Clinical Trial Detail

NCT ID NCT00912340
Title Randomized Phase II Trial of Trastuzumab or EVEROLIMUS in Hormone-refractory Metastatic Breast Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Emory University
Indications

breast cancer

Therapies

Everolimus

Trastuzumab

Age Groups: adult

Additional content available in CKB BOOST